Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its personalized healthcare solutions and momentum in weight loss offerings. Management highlighted that expanding the range of treatments, such as the addition of liraglutide and branded Wegovy through a new partnership with Novo Nordisk, was key to attracting new subscribers. CEO Andrew Dudum emphasized, “Our vision involves expanding from hundreds of personalized treatments today to potentially thousands, powered by richer insights from lab diagnostics, growing subscriber data sets, and eventually daily tracking from wearable devices.”

Is now the time to buy HIMS? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Hims & Hers Health’s Q1 Earnings Call

• Craig Hettenbach (Morgan Stanley) asked about key drivers for weight loss revenue and the impact of new product launches. CEO Andrew Dudum highlighted the addition of liraglutide and branded options as central to sustaining growth in the segment.
• Maria Ripps (Canaccord Genuity) inquired about initiatives to reaccelerate growth in the sexual health vertical. Dudum explained the transition to daily, multi-condition care and the focus on higher retention products.
• Eric Percher (Nephron Research) questioned the balance between personalized and branded GLP-1 medications. Dudum reiterated that clinical decisions remain with providers and that personalized offerings are reserved for specific patient needs.
• Daniel Grosslight (Citi) sought clarity on the Novo Nordisk partnership and the handling of personalized semaglutide. Dudum stated that corporate does not influence clinical decisions, maintaining a separation between provider autonomy and business operations.
• David Larsen (BTIG) asked about the potential for integrating insurance and relationships with drug manufacturers. Dudum said there is little interest in insurance integration due to complexity and inefficiency, emphasizing a cash-pay model for most everyday healthcare needs.

Catalysts in Upcoming Quarters

In the coming quarters, our team will track (1) the pace of subscriber adoption for new daily and personalized treatments, (2) the rollout and consumer uptake of low testosterone and menopause support offerings, and (3) progress in integrating lab diagnostics into the platform. Execution in expanding partnerships and improving operational efficiency will also be key milestones.

Hims & Hers Health currently trades at $47.98, up from $41.95 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.